For research use only. Not for therapeutic Use.
Remimazolam（Cat No.:I009004）is a fast-acting benzodiazepine used for procedural sedation and general anesthesia. It works by enhancing the activity of GABA, the brain’s primary inhibitory neurotransmitter, leading to sedation, anxiolysis, and muscle relaxation. Due to its rapid onset and short duration of action, Remimazolam provides precise control over sedation levels, making it ideal for short procedures. Its quick metabolism by tissue esterases minimizes the risk of prolonged sedation and respiratory depression, offering a safer alternative for patients with compromised organ function compared to traditional sedatives.
| Catalog Number | I009004 |
| CAS Number | 308242-62-8 |
| Synonyms | CNS-7056; CNS 7056; CNS7056; Remimazolam;methyl (S)-3-(8-bromo-1-methyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,2-a][1,4]diazepin-4-yl)propanoate |
| Molecular Formula | C21H19BrN4O2 |
| Purity | 95% |
| Target | GABRG3 |
| Target Protein | Q99928 |
| Solubility | Soluble in DMSO, not in water |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IUPAC Name | methyl 3-[(4S)-8-bromo-1-methyl-6-pyridin-2-yl-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate |
| InChI | InChI=1S/C21H19BrN4O2/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21/h3-6,8,10-12,17H,7,9H2,1-2H3/t17-/m0/s1 |
| InChIKey | CYHWMBVXXDIZNZ-KRWDZBQOSA-N |
| SMILES | CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=N[C@H]2CCC(=O)OC)C4=CC=CC=N4 |
| Reference | </br>1:Inhaled Remimazolam Potentiates Inhaled Remifentanil in Rodents. Bevans T, Deering-Rice C, Stockmann C, Rower J, Sakata D, Reilly C.Anesth Analg. 2017 May;124(5):1484-1490. doi: 10.1213/ANE.0000000000002022. PMID: 28333705 </br>2:Metabolite characterization of a novel sedative drug, remimazolam in human plasma and urine using ultra high-performance liquid chromatography coupled with synapt high-definition mass spectrometry. Zhou Y, Hu P, Jiang J.J Pharm Biomed Anal. 2017 Apr 15;137:78-83. doi: 10.1016/j.jpba.2017.01.016. Epub 2017 Jan 12. PMID: 28104560 </br>3:Remimazolam: Pharmacologic Considerations and Clinical Role in Anesthesiology. Wesolowski AM, Zaccagnino MP, Malapero RJ, Kaye AD, Urman RD.Pharmacotherapy. 2016 Sep;36(9):1021-7. doi: 10.1002/phar.1806. Epub 2016 Sep 1. Review. PMID: 27496519 </br>4:A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopy. Pambianco DJ, Borkett KM, Riff DS, Winkle PJ, Schwartz HI, Melson TI, Wilhelm-Ogunbiyi K.Gastrointest Endosc. 2016 May;83(5):984-92. doi: 10.1016/j.gie.2015.08.062. Epub 2015 Sep 9. PMID: 26363333 </br>5:Fospropofol and remimazolam. Ilic RG.Int Anesthesiol Clin. 2015 Spring;53(2):76-90. doi: 10.1097/AIA.0000000000000053. Review. No abstract available. PMID: 25807020 </br>6:A Phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy. Borkett KM, Riff DS, Schwartz HI, Winkle PJ, Pambianco DJ, Lees JP, Wilhelm-Ogunbiyi K.Anesth Analg. 2015 Apr;120(4):771-80. doi: 10.1213/ANE.0000000000000548. PMID: 25502841 </br>7:Simultaneous determination of remimazolam and its carboxylic acid metabolite in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry. Zhou Y, Wang H, Jiang J, Hu P.J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jan 22;976-977:78-83. doi: 10.1016/j.jchromb.2014.11.022. Epub 2014 Dec 2. PMID: 25486614 </br>8:Remimazolam: The future of its sedative potential. Goudra BG, Singh PM.Saudi J Anaesth. 2014 Jul;8(3):388-91. doi: 10.4103/1658-354X.136627. Review. PMID: 25191193 Free PMC Article</br>9:A phase Ib, dose-finding study of multiple doses of remimazolam (CNS 7056) in volunteers undergoing colonoscopy. Worthington MT, Antonik LJ, Goldwater DR, Lees JP, Wilhelm-Ogunbiyi K, Borkett KM, Mitchell MC.Anesth Analg. 2013 Nov;117(5):1093-100. doi: 10.1213/ANE.0b013e3182a705ae. PMID: 24108261 </br>10:Context sensitive decrement times of remimazolam. Schnider T, Minto C.Anesth Analg. 2013 Jul;117(1):285. doi: 10.1213/ANE.0b013e3182942954. No abstract available. PMID: 23788743 |
